Background: Due to the MCH1 receptor being a target of long standing interest in the pharmaceutical industry, there is interest in generating a MCHR1 receptor occupancy (RO) ligand suitable for in vivo imaging experiments to facilitate drug discovery efforts and ultimately for translation to a human PET tracer. However, the identification of robust clinical and pre-clinical target engagement biomarkers for this target has remained a challenge. Recently, the BANYU group reported high affinity radiotracer with low non-specific binding, however it suffered from low brain penetration making it unsuitable as an in vivo RO ligand. A subsequent publication from the BANYU group reported molecules with improved brain penetration. Methods: Herein is an analysis of the SAR disclosed by BANYU combined with the use of computational models to predict parameters related to brain penetration and non-specific binding.
Background: Monoamine oxidases (MAO) are important enzymes regulating the levels of monoaminergic neurotransmitters and bioactive monoamines by catalyzing their deamination. MAO-B inhibitors are widely used in the treatment of e.g. Parkinson's disease (PD) and depression. L-Deprenyl is a selective MAO-B inhibitor, has been labeled with 11 C and used in PET studies to image the distribution of available MAO-B in the human brain. 1 In the brain regions being rich in MAO B, the tracer is trapped at a rate which exceeds the rate at which it is delivered by the plasma. Bis-deuterium-substituted L-deprenyl ([ 11 C]L-deprenyl-D2) has been introduced to reduce the rate of radiotracer trapping in the human brain. 2 Carbon-11 labeled compounds are less suitable for distribution to external clinics because of its relatively short half-life. Recently, we reported a novel fluorine-18 labeled fluoro analogue of Ldeprenyl to image MAO-B in monkey brain. 3, 4 In this project our aim was to develop a fast and efficient synthetic method for labeling novel bis-deuterium substituted L-deprenyl analogues with fluorine-18 towards N-[(2S)-1-[ 18 F]fluoro-3-phenylpropan-2-yl]-N-methyl(1,1-2 H 2 )prop-2-yn-1-amine ([ 18 F]fluorodeprenyl-D2). Methods: In vitro MAO inhibition was determined for 19 F-fluorodeprenyl-D2 in an enzymatic assay with kynuramine as substrate using pargyline and L-deprenyl as control inhibitors for MAO-B and clorgyline as control inhibitor for MAO-A. Precursor (5) was synthesized in multi-step syntheses ( Figure 1 ). Radiolabeling was accomplished by a one-step nucleophilic substitution reaction towards [ 18 F]fluorodeprenyl-D2 (Figure 1 ). Uptake and binding of compound 6 were examined in a cynomolgus monkey brain by PET. Radiometabolites were measured in monkey plasma using gradient HPLC. Results: Fluorodeprenyl-D2 inhibited the MAO-B activity with an IC 50 of 227 ± 36.8 nM (L-deprenyl = 13 ± 0.4 nM) and the MAO-A activity with an IC50 of > 50 mM. The radiolabeling was achieved by one step nucleophilic substitution reaction of the chloride precursor (5) by [ 18 F]fluoride in anhydrous DMSO. The overall radiosynthesis including fluorination, HPLC purification and radiotracer formulation was completed in 80 minutes. The incorporation yield of the fluorination reactions was > 70%, the radiochemical purity was > 99% and the specific radioactivity > 200 GBq/mmol at the time of administration. The radioligand [ 18 F]fluorodeprenyl-D2 was found to be stable, with a radiochemical purity of more than 99% at 3 h after formulation in a sterile phosphate buffered solution (pH = 7,4). In vivo there was a high uptake in the monkey brain (240 SUV (%) at 4 min) with higher amounts in the striatum and thalamus compared to the cortex and cerebellum ( Figure 2 ). Metabolite studies demonstrated 40% unchanged radioligand at 120 min post injection. Conclusions: Radiolabeling of a novel fluorine-18 analogue of bis-deuterium substituted L-deprenyl (6) was performed. Compound 6 binds specifically to MAO-B and is enhanced in MAO-B rich regions in the monkey brain. This radioligand [ 18 F]fluorodeprenyl-D2 may be a potential candidate for human PET studies. P071. Specificity assessment of the GABA A receptor a5 subtype preferring radiotracer [ 3 
References

H]RO15-4513
Michael Honer, Maria-Clemencia Hernandez, Luca Gobbi, Thomas Hartung, Laurence Ozmen and Edilio Borroni F. Hoffmann-La Roche Ltd, Basal, Switzerland Background: RO15-4513 is a well-established partial inverse agonist at the GABA A receptor showing preferential binding to the a5-subunit containing receptor subtype (GABRA5). Tritiated RO15-4513 as well as [ 11 C]-labeled RO15-4513 are widely used tools to analyze the GABRA5 subtype in vitro and in vivo. The aim of this study was to investigate in detail the in vitro binding specificity of RO15-4513 for the GABRA5 subtype. Methods: A CEREP s screen of RO15-4513 was performed to test ligand binding to a battery of more than 80 CNS targets. Sagittal brain sections of GABRA5 knockout mice and wildtype controls were used for specificity assessment of the tritiated radioligand by in vitro autoradiographical analysis. [ 3 H]RO15-4513 binding (at 0.1 nM) was quantified in absence and presence of various blockers with different subunit specificity and compared with the non-selective GA-BA A receptor radiotracer [ 3 H]RO15-1788 (Flumazenil).
Results:
The pharmacological specificity of RO15-4513 for the GABA A receptor was confirmed by a broad CEREP s screen where 10 mM RO0154513 showed binding potency only at the GABA A receptor. In wildtype mouse brains highest binding of [ 3 H]RO15-4513 was identified in the hippocampus followed by cortex and pons ( Figure 1A) . In brain sections of GABRA5 knockout animals radioligand binding in the hippocampus was reduced by 84% whereas considerable residual binding of [ 3 H]RO15-4513 ( > 50% of total binding) was found in other brain regions ( Figure 1B ). Co-incubation with Zolpidem, a ligand with high affinity for a1, a2 and a3subunit containing receptor subtypes and no affinity for GABRA5, revealed a fairly pure GABRA5 binding signal in wildtype mouse brains ( Figure 1C ). This finding was corroborated by an almost complete blockade of [ 3 H]RO15-4513 binding by Zolpidem in GABRA5 knockout brains only leaving some mini- mal binding to a4 and a6-subunit containing receptor subtypes expressed in the cerebellum ( Figure 1D ). Flumazenil binding in GABRA5 knockout brains was marginally reduced compared to wildtype controls confirming that GABRA5 represents a minor subtype compared to the total GABA A receptor population. Conclusions: This study confirms the preferential binding of [ 3 H]RO15-4513 to GABRA5 in vitro. However, in brain regions with relatively low abundance of GABRA5 (i.e. all brain regions except the hippocampus) the in vitro specificity of [ 3 H]RO15-4513 for GABRA5 is limited even at concentrations well below the Ki value of the radioligand for GABRA5. Co-administration of Zolpidem may provide an opportunity to target and quantify GABRA5 more specifically. Novel tracers with selectivity ratios of more than 20 fold for GABRA5 over other GABA A receptor subtypes will be desirable for a more reliable quantification of GABRA5 in vitro and in vivo.
P072. Radioiodinated reboxetine analogues for imaging of the norepinephrine transporters in brain using single photon emission computed tomography
Background: 123 I-INER, a radioiodinated (S,S) reboxetine analogue, and 123 I-NKJ64, a radioiodinated (R,S) stereoisomer of 123 I-INER, are the most promising radiotracers developed to date for in vivo imaging of the norepinephrine transporter (NET) using single photon emission computed tomography (SPECT) [1] [2] [3] [4] . The present study aimed to compare the brain distribution and pharmacokinetics of 123 I-NKJ64 with that of 123 I-INER in baboons and to investigate the occupancy of NET in baboons using SPECT in order to determine the most promising radioiodinated reboxetine analogue.
Methods: Adult female baboons (Papio anubis) were anesthetized and imaged on a Neurofocus SPECT camera (NeuroPhysics, Sharon, MA, USA). For the first experiments, baboons received a bolus of either 123 I-INER or 123 I-NKJ64 intravenously and arterial blood was sampled during the SPECT acquisition. Image analysis; invasive and noninvasive kinetic modelling were performed using PMOD 3.203 software (PMOD technologies, Zurich, Switzerland). 123 I-INER was also used to estimate receptor occupancy by bolus plus constant infusion studies with displacement at equilibrium using six different doses of atomoxetine (0.03 to 0.85 mg/kg) and four different doses of reboxetine (0.5 to 3.0 mg/kg). Results: Following bolus injection, both radiotracers rapidly and avidly entered the baboon brain. The regional brain accumulation of 123 I-NKJ64 did not match the known distribution of NET in baboon brain (highest in brainstem), contrasting with previous results obtained in rats [4] . Conversely, the regional distribution of 123 I-INER was consistent with the known distribution of NET in baboon brain (Table) . Since 123 I-INER was found to be the preferred radioiodinated reboxetine analogue, occupancy measures of NET in baboon brain were determined using SPECT. After administration of atomoxetine or reboxetine, a dose-dependent occupancy was observed in brain regions known to contain high densities of NET (atomoxetine ED 50 = 0.10 mg/kg and reboxetine ED 50 = 1.07 mg/kg). Conclusions: These data suggest that 123 I-NKJ64 may lack affinity and selectivity for NET in baboon brain. 123 I-INER is the most promising SPECT radioiodinated reboxetine analogue developed to date for in vivo imaging of NET in brain. Dose-dependent NET occupancy for two selective norepinephrine reuptake inhibitors was successfully measured in vivo in baboon brain using SPECT and 123 I-INER. These results highlight the importance of species differences during radiotracer development and the enantioselectivity of radioiodinated analogues of reboxetine in vivo. Acknowledgements: Adriana Tavares was funded by a scholarship from the Scottish Imaging Network: A Platform for Scientific Excellence (SINAPSE) Collaboration.
Background: Phosphodiesterase 10A (PDE10A) is a dual phosphodiesterase that hydrolyzes both cyclic nucleotides cAMP and cGMP. PDE10A is expressed in the testes to a low level in contrast to the brain where PDE10A is abundantly expressed and restricted in the striatum within the GABAergic medium spiny neurons. This highly localized expression pattern stimulates immediate interest in a potential role of the inhibition of PDE10A as a new therapeutic approach in treating neurological and psychiatric disorders. RO6802488 is a potent PDE10A inhibitor (pIC 50 = 8.3) with favorable lipophilicity (logD = 2.9) for a CNS radiotracer. The aim of this study was to evaluate RO6802488 in vitro and in vivo for its use as radiotracer to specifically visualize and quantify PDE10A in the brain. Methods: [ 3 H]-RO6802488 and [ 11 C]-RO6802488 were prepared from a common precursor by a methylation reaction with [ 3 H]MeNs or [ 11 C]MeI. Sagittal rat brain sections were used for specificity assessment of the tritiated radioligand by in vitro autoradiographical analysis. In vitro autoradiography studies with [ 3 H]-RO6802488 were compared on rat, Cynomolgus monkey, baboon and human brain slices. Ex vivo autoradiography of [ 3 H]-RO6802488 and tissue sampling were performed to assess in vivo tracer distribution and kinetics in the rat brain. Blockade experiments were performed both in vitro and in vivo with a structurally different PDE10A inhibitor. These data were compared with [ 11 C]-RO6802488 PET data obtained in rat and in baboon. Results: [ 3 H]-RO6802488 showed predominant in vitro binding in the striatum, the substantia nigra and the tubercule olfactorium. A comparable distribution was observed in Cynomolgus monkey, baboon and human brain samples. Specificity of the radioligand for PDE10A was demonstrated by a full blockade of binding using co-incubation with a structurally dissimilar PDE10A inhibitor. In vivo, [ 3 H]-and [ 11 C]-RO6802488 showed good uptake into the rat brain with a regional distribution in agreement with the in vitro experiments. Tracer peak concentrations were reached at 30-40 min post administration followed by a washout phase. Significant blockade of tracer uptake was achieved by pretreatment of the animals with a structurally different PDE10A inhibitor. In baboons, [ 11 C]-RO6802488 demonstrated moderate brain uptake and slow washout kinetics. HPLC analysis of plasma samples indicated rapid metabolism of [ 11 C]-RO6802488, with approximately 50% of parent radiotracer left after the first 10 min and one single more polar radiometabolite being formed in minor amounts. Despite the favorable metabolic pattern in plasma, a constant increase in radioactivity was observed in regions with low PDE10A density which might be attributed to a brain penetrant radiometabolite.
Conclusions: RO6802488, labeled with [ 3 H] or [ 11 C], is a specific radioligand/tracer for PDE10A with favorable characteristics for in vitro and in vivo evaluation of PDE10A in the rodent brain. The presence of a putative brain penetrant radiometabolite in the baboon suggests that this tracer is not suitable for in vivo evaluation of PDE10A in nonhuman primate brain.
P074. Modelling of the novel P-gp expression tracer [ 11 C]laniquidar: a test-retest study in healthy volunteers
Background: Overexpression of P-glycoprotein (P-gp) is thought to play a role in drug resistance, affecting 30% of patients with epilepsy. Laniquidar is supposed to be an inhibitor of P-gp and, therefore, overexpression of P-gp should lead to an increased signal. The aims of this first-in-man study were to characterize [ 11 C]laniquidar kinetics in human subjects and to develop a tracer kinetic model for analyzing [ 11 C]laniquidar data. Methods: Dynamic 60 minutes [ 11 C]laniquidar PET scans (24 frames) were performed in 11 healthy volunteers using an HR + scanner (CTI/Siemens). Plasma input functions were obtained using an on-line sampling device, with metabolite correction based on up to 7 manual HPLC processed samples. T1-weighted MRI scans were acquired on a SONATA 1.5T scanner (Siemens) and used for co-registration and volume of interest delineation. Regional time activity curves were fitted to various one and two tissue compartment models in order to identify the best model describing [ 11 C]laniquidar kinetics.
Results: Modelling was compromised by the low first-pass extraction fraction of [ 11 C]laniquidar, which was estimated to be 2-3%. Metabolism of [ 11 C]laniquidar in plasma was fast (only 50% of parent tracer remaining after 10 minutes, 20% after 60 minutes). Both standard single and two tissue compartment models did not fit the data well, with k 2 values that were too small to be estimated reliably. In all subjects, cerebral [ 11 C]laniquidar concentrations started to increase after 5-10 minutes. The quality of the fits improved significantly by adding a second parallel (single tissue) compartment with one of the labelled plasma metabolites as input function, suggesting that metabolites enter the brain. The most robust model was found to be an irreversible single tissue compartment model providing estimates for K 1 and V b and using only the first 3 minutes of PET data in order to prevent the contribution of labelled metabolites. For this model, the mean ( ± SD) of K 1 was 0.019 ± 0.004. Initial test-retest studies showed a significant increase in K 1 in the afternoon scan. Interestingly, however, after standardizing breakfast and lunch, reproducibility of K 1 improved. Conclusions: [ 11 C]laniquidar kinetics suggest that labelled metabolites enter the brain. Indeed, a dual input model with both parent tracer and metabolite as input functions provided the best fits to full 60 minutes data. If parent plasma is used as input Background: Positron emission tomography (PET) is a sensitive in vivo imaging technique in which compounds with short lived radionuclides such as 18 F and 11 C are administered via intravenous injection and used for quantitative measurements of biochemical processes. However, a drawback with PET is that it only reflects the total amount of radioactivity in tissue and does not provide any information on its chemical form. Therefore it is important to develop methods by which radiometabolites of Based on these findings and the use of fast radio-LC 2 , which allowed the achievement of higher peak resolution and sensitivity in a shorter time frame compared to conventional methods, it was possible to further identify and determine the relative abundance of [ 18 F]FE-PE2I and its radiometabolites over time in plasma of different species as well in rat brain. In plasma samples of all the studied cases carboxyl [ 18 F]FE-PE2I was the most abundant radiometabolite found. However, in rat striatum hydroxyl [ 18 F]FE-PE2I had the highest presence.
Conclusions: The work flow presented here can be used to successfully identify and measure radiometabolites of PET radioligands in general. This enables us to predict the presence and degree of significance of the more lipophilic radiometabolites, which have the potential of crossing the blood brain barrier.
Background: Due to limitations by the short half-life of the gold-standard SERT-radiotracer [ 11 C]DASB, its moderate cortical test retest reliability, and the lack of options for quantifying endogenous serotonin, fluorine-18-labelled compounds for imaging the brain SERT are of unmet interest. Here, we report on our first application in man of a new fluorine-18 labelled fluoromethyl analogue of ( + )-McN5652 (( + )-[ 18 F]FMe-McN5652) and its potential for SERT quantification. Methods: Five healthy volunteers (3 male, 2 female, age 39±10 years) were included in the study. The PET data were analysed by individual MRI-based volumeof-interest analysis (PMOD). Rate constants and total distribution volumes (V T ) were calculated using a 2tissue compartment model and arterial input function measurements corrected for metabolites. Standardized uptake region-to-cerebellum ratios (SUVR) as measure of specific radiotracer accumulation were compared Figure) . The 2-tissue compartment model provided adequate fits to the data. Estimates of total distribution volume (V T ) demonstrated good identifiability based on coefficient of variation (COV) for the volumes of interest (VOIs) in SERT-rich and also for cortical areas (COV V T < 10%). Regional SUVR of ( + )-[ 18 F]FMe-McN5652 and [ 11 C]DASB were highly correlated (R = 0.94, P < 0.001) and significantly different with lower values of the 18 F-labelled derivative and less standard deviation in most of the regions, in particular in the raphe region, but not in the nucleus accumbens (Table) .
Conclusions:
The results showed that ( + )-[ 18 F]FMe-McN5652 is suitable for in vivo visualisation and quantification of SERT with PET bearing also potential for widespread use and further tracer kinetic studies, i.e. to reveal its sensitivity for endogenous serotonin.
P078. Measuring non-specific binding of novel PET radioligands to determine structure-activity relationships between NSB and their physiochemical properties
Chloe Child 1 , Antony Gee 1 , Nicholas Long 2 and Oscar Ces 2 1 Kings College London, UK; 2 Imperial College, London, UK Background: The non-invasive imaging modality positron emission tomography (PET) is used extensively in clinical settings and is increasingly being used by the pharmaceutical industry in drug development.
Molecules of biological interest are labelled with positron emitting isotopes e.g. 11 C, allowing their biodistribution and kinetics to be followed in vivo. A major factor in the failure of radioligands is the magnitude of unwanted background signal, non-specific binding (NSB) obscuring binding to the desired target.
Assumptions have previously been made as to the physiochemical and pharmacological properties of radioligands that can affect NSB. However, little work has been carried out to quantify NSB with regard to determining structure-activity relationships (SARs) in order to optimise efficient radiotracer discovery.
Methods: Non-specific binding is a poorly understood process but is believed to be related to the non-saturable binding of labelled molecules with tissue membranes. In this work the synthesis of novel radiolabelled molecular libraries has been conducted, their physicochemical properties determined and their non-specific binding measured in vitro using autoradiographical and cell based mass spectrometry assay methods. Structure-activity relationships have been formed between partition coefficient properties, acid dissociation constants, interaction energies and molecular weight in order to determine the effect each of these properties has on non-specific binding.
Results: Traditionally lipophilicity, log P, of a radioligand is the main predictor to its non-specific binding properties. However, from this work, it has been shown that a single physicochemical property cannot be relied on to predict the NSB of a radioligand.
Conclusions: Multiple properties must be considered.
P079. Development of an 18 F-labelled 5-HT 2A receptor agonist PET radioligand Background:
We have recently validated a series of N-benzylphenethylamine-based agonists as promising positron emission tomography (PET) tracers for quantification of serotonin 2A (5-HT 2A ) receptor binding in the living brain (1, 2) . An agonist 5-HT 2A receptor radioligand is hypothesized both to provide a more relevant measure of the 5-HT 2A receptors and also to be more susceptible to changes in endogenous serotonin as compared with 5-HT 2A receptor antagonist tracers. Thus, a 5-HT 2A receptor agonist PET radioligand may reflect endogenous serotonin levels in the living brain. So far, all these radioligand have been labelled with C-11. However, labelling a PET radioligand with the longer-lived 18 F-isotope offers distinct advantages including better count statistics in longer scans making e.g. bolus-infusion paradigms more easily applicable. Furthermore, 18 F-labelled radioligands can be distributed to PET centers that do not have an on-site cyclotron. Here, we report the radiosynthesis and evaluation of three novel N-benzylphenethylamine 18 F-labelled 5-HT 2A receptor agonist PET tracers.
]Cimbi-320) by radio-fluorination of the N-Boc-protected precursors. We studied the in vivo brain distribution of the tracers in three female Danish Landrace pigs. After intravenous administration of each tracer, the pigs were scanned for 150 minutes in list-mode in a high resolution research tomography (HRRT) scanner. In all scans, the 5-HT 2A receptor antagonist ketanserin was injected i.v. after 90 min as a within scan challenge. Arterial blood samples and radiometabolite analyses were done in all pigs to compute arterial input functions, and brain regional radioactive concentrations were obtained after co-registration to a MRIbased atlas of the pig brain. Furthermore, in vitro receptor autoradiography was perfomed with [ 18 F]Cimbi-320 on pig and rat brain sections.
Results: The in vitro receptor autoradiography showed that [ 18 F]Cimbi-320 binding on pig brain sections was in accordance with the expected 5-HT 2A receptor distribution. Furthermore, the [ 18 F]Cimbi-320 binding was completely displaced by ketanserin confirming the 5-HT 2A receptor affinity of this compound in vitro. The in vivo PET scans showed that [ 18 F]Cimbi-362, [ 18 F]Cimbi-360, and [ 18 F]Cimbi-320 entered the pig brain in insufficient amounts, and the peak brain uptake was 1 SUV, 0.7 SUV, and 1.3 SUV, respectively. Furthermore, the PET scan of [ 18 F]Cimbi-320 showed extensive skull uptake indicating rapid defluorination in vivo. For all three compounds, the uptake was lower in brain tissue as compared to the surrounding tissue. This suggest that these PET radioligands undergo rapid defluorination in vivo (to yield free 18 F-fluoride which is deposited in bone) or that they interact with an active efflux transporter such as P-glycoprotein. The insufficient brain uptake could also arise from to a combination of these factors. labelled agonist for opioid receptor (OR) imaging [1] .
[ 18 F]FEPEO is a full agonist active at m-, d-, and k-ORs, with profound selectivity for the k-OR and m-OR.
Cerebral distribution of ([ 18 F]FEPEO) in Lister-Hooded rats was investigated and ROI data was quantified.
Methods: The non-radioactive reference compound FEPEO and a labelling precursor for direct nucleophilic radiofluorination were prepared. An automated process for the production of [ 18 F]FEPEO using a GE Tracerlab FXFN radiosynthesis module was developed. The radiotracer was subjected to in vitro and ex vitro autoradiography studies in rat brain sections. Radiotracer uptake into OR containing brain regions was investigated using microPET. The amount of radioactive metabolites in plasma and brain tissue was determined. Radiotracer uptake into a variety of brain regions was quantified using RTM, sRTM, invasive and non-invasive Logan graphical analysis, 1-tissue compartment and 2-tissue compartment plasma input modelling [3] . Results: [ 18 F]FEPEO was obtained in a radiochemical yield (RCY) of 30 ± 25% (n = 16) via nucleophilic substitution using a trityl protected labelling precursor and subsequent cleavage of an O-trityl protective group. Radiotracer distribution mirrored the distribution of ORs in the rat brain. Radiotracer binding was found to be reversible and saturable via antagonist treatment. The cerebellum was validated as a suitable reference region for reference tissue modelling.
Conclusions: [ 18 F]FEPEO was produced using an automated process using cGMP compliant equipment. This OR agonist showed selective and saturable uptake into OR containing brain regions with profound selectivity for the MOR in rats. This is the first validated 18 F-labelled OR full agonist PET tracer available for PET. The cerebellar cortex is a suitable reference region for kinetic modelling of [ 18 F]FEPEO-PET data. 306 ± 32%, p = 0.1) and faster wash-out (peak-to-120 min ratio: 2.8±0.5 vs. 2.3-0.5, p = 0.07) ( Figure) .
BP Results: All three ligands showed favorable properties for PET imaging with sufficient brain exposure, reversible binding with rapid binding kinetics, as well as high specific and low non-specific binding. The time-activity curves could be described by a 2-tissue compartment model as well as be fitted using the Logan plot. The radioligands could be quantified using simplified reference regions methods which were validated against full kinetic modeling (Figure 1 
Conclusions:
The individual characteristics of the three radioligands may translate into advantages for different imaging purposes. For multi-tracer approaches an carbon-11 labeled ligand, such as [ 11 C]AZD2184, is advantageous due to the potential to perform several PET measurements in the same subject on the same day. [ 11 C]AZD2184 having high discriminate power can serve as a tool to study discrete levels of amyloid-b, which may be important in early prodromal stages of AD or in longitudinal studies of disease modifying therapies. Being labeled with the more long-lived radionuclide Fluor-18, allowing shipment to PET-facilities without their own cyclotrone, [ 18 F]AZD4694 has potential as a biomarker to assist the clinical diagnosis of Alzheimer's Disease. [ 11 C]AZD2995, with its very low nonspecific binding, may provide advantages for micro-PET studies on transgenic rodents. We conclude that the present development of three novel radioligands for amyloid-b PET imaging have the potential to serve research and clinical applications in several ways.
Background: Many neurological disorders are associated with imbalances in protein acetylation and transcriptional dysfunction for which histone deacetyl-ases (HDACs) play an important role. 1 Aberrant acetylation of a-tubulin, a major substrate of HDAC6, leads to defects in intracellular transport that have been linked to neurodegenerative disorders, such as Alzheimer's disease 2 and Huntington's disease. 1 Tubastatin A is a selective HDAC6 inhibitor which has been shown to induce elevated levels of acetylated a-tubulin, confer dose-dependent protection against glutathione depletion-induced oxidative stress in primary cortical neuron cultures and restore defects in axonal transport. 3, 4 In this work, we aimed to develop a generic method for labeling hydroxamic acids with carbon-11 that could be used to prepare [ 11 C]tubastatin A as a candidate PET radioligand for imaging HDAC6 in the brain. This method should also be applicable to labeling other hydroxamic acids as potential PET radioligands.
Background: The metabotropic glutamate subtype 2 receptor (mGluR2) is a presynaptic membrane receptor distributed widely in brain that provides feedback inhibitory control of glutamate release. Augmenting mGluR2 function with a positive allos-teric modulator (PAM) is expected to reduce activity dependent glutamate release which may be of therapeutic benefit for a range of neurological and psychiatric disorders. To confirm target engagement and define exposure-occupancy relationships of clinical candidates targeting this site, a site-specific positron emission tomography (PET) ligand has been developed. Here we report the preclinical evaluation of [ 11 C]JNJ42491293, a PET ligand for in vivo imaging of mGluR2 in brain. Methods: The chloro-triazolopyridine JNJ42491293 was selected based on affinity and selectivity for an mGluR2 allosteric site and acceptable physicochemical properties. [ 11 C]JNJ42491293 was obtained by alkylation of the phenolic precursor with [ 11 C]MeI followed by RP-HPLC purification. Biodistribution and mPET imaging were performed in rats. Radiometabolites were quantified in rat plasma and brain homogenates using HPLC. Blocking and displacement experiments were done using compounds with high affinity and selectivity for mGluR2. Results: In vitro radioligand binding studies showed that JNJ42491293 binds with high affinity (IC50 = 9.6 nM) to the cloned human mGlu2 receptor. Further studies demonstrated that JNJ-42491293 acted as a PAM with a potency of 7.6 nM. JNJ-42491293 showed > 250-fold selectivity versus other mGlu receptors or neurotransmitter targets. [ 11 C]JNJ 42491293 was obtained with a radiochemical yield of 65% and a specific activity of 145 GBq/mmol. Rat biodistribution studies showed moderate brain uptake (0.88% ID at 2 min p.i.) and accumulation of radioactivity in all studied brain regions ( > 1% ID at 30 min p.i.) such as cortex, striatum, and cerebellum, consistent with the known distribution of the mGlu2 receptor. Plasma radiometabolite analysis showed the presence of one polar metabolite which was not detected in brain. Baseline mPET imaging showed that the maximum radioactivity concentration (SUV 1.7) in brain was reached at 12 min p.i., remained constant until 27 min, followed by slow wash-out. Blocking resulted in fast wash-out and chasing in displacement of radioactivity in all studied brain regions.
Conclusions: mPET blocking and displacement experiments in rats indicate that [ 11 C]JNJ42491293 binds specifically and reversibly to an mGluR2 allosteric site, strongly suggesting that it is a promising candidate for in vivo imaging of mGluR2 using PET.
P088. 11 C-TAZA and 11 C-Dalene: new PET imaging agents for human brain senile plaques also bind to norepinephrine transporter Background: Alzheimer's disease (AD) is a neurodegenerative disease characterized by b-amyloid senile plaques (SPs) that reside mainly in the frontal cortex and hippocampus regions of the brain. The aim of this study is to evaluate the effectiveness of two new tracers, 4-11 C-methylamino-4 0 -dimethylaminoazobenzene ( 11 C-TAZA) and 4-methylamino-4 0 -(N-11 Cmethyl-N-methylamino)stilbene ( 11 C-Dalene) shown in Figure 1 . Binding of 11 C-TAZA, 11 C-Dalene and 11 C-PIB was evaluated to the SP sites in post-mortem human brain hippocampus (AD and control) and binding to norepinephrine transporters (NET) were evaluated in normal rats using PET/CT. Methods: Radiosynthesis was carried out by reacting 4-amino-4 0 -dimethylaminoazobenzene (1 mg/0.5 cc acetone for 11 C-TAZA) and 4-methylamino-4 0 -(Nmethylamino)stilbene (1 mg/0.5 cc acetone for 11 C-Dalene) with 11 C-methyltriflate prepared in the GE FXCPro synthesis unit. 11 C-Methyltriflate was trapped at À20 o C, subsequently heated for 5 mins at 80 o C and purified using HPLC. In vitro autoradiography studies were performed on 7 micron slices of hippocampus of AD patients and control brains. Slices were incubated with the radiotracer (10-25 mCi/cc, 11 C-TAZA, 11 C-Dalene or 11 C-PIB) in 40% ethanol-water for 1/2 hour. Non-specific binding was assessed using 10 mM PIB for the 3 tracers. Slices were then washed and exposed on to phosphor screens and slides were analysed by Optiquant image analysis program for SP binding Digital light units/ mm 2 (DLU/mm 2 ). Sprague-Dawley rats were scanned after IV injection of 11 C-TAZA and 11 C-Dalene in Inveon PET/CT and displacement studies were done with atomoxetine (1 mg/kg). PET images were analysed using PMOD.
Results: 11 C-TAZA, 11 C-Dalene and 11 C-PIB were obtained in 25 to 100 mCi yields in specific activities > 1000 Ci/mmol. The radiosynthesis was clean with > 95% radiochemical product for each of them. 11 C-TAZA and 11 C-Dalene bound specifically to SP present in AD brains compared to the normal controls as show in the Figure 1 . AD/Control hippocampus ratios were: 11 C-TAZA > 30; 11 C-Dalene > 5 and 11 C-PIB > 5. Presence of SP in the AD brains were confirmed using 4G8 antibody immunostaining for Ab-amyloid. The control brains exhibited little or no SP. Unlabeled PIB dispaced 11 C-TAZA and 11 C-Dalene-suggesting similar binding sites. 11 C-TAZA and 11 C-Dalene also exhibited selective binding in NET brain regions such as brain stem and thalamus. Ratios of brain stem to cingulate gyrus (used as reference region) was > 2. Atomoxetine reduced the binding of both 11 C-TAZA and 11 C-Dalene with the former showing greater reduction.
Conclusions: Our studies suggest that 11 C-TAZA and 11 C-Dalene are effective imaging agents for human SP in AD patients. Of the 3 radiotracers, 11 C-TAZA showed the highest binding to SP. Our studies also suggest that 11 C-TAZA and 11 C-Dalene bind to NET. Further studies are underway to determine if there is overlap in the binding sites of SP and NET. Acknowledgements: NIH/NIA R01AG029479, NIH/ NIA R33AG030524, NIH/NIA P50 AG16573. Background: Innervation of brown adipose tissue (BAT) with neurotransmitter, norepinephrine is essential for regulation of thermogenesis and thus has a role in obesity and diabetes. Norepinephrine acts by activating b3-adrenoceptor to increase BAT metabolic activity measurable using 18 F-FDG PET. Norepinephrine transporter (NET) inhibitors such as atomoxetine play an important role in BAT activity by increasing norepinephrine levels. Therefore imaging NET along with glucose metabolism in BAT will provide useful tools to measure mass and activity of BAT.
Methods: Male Sprague-Dawley rats were fasted for 24 hrs prior to 18 F-FDG administration. Rats were administered iv B0.3 mCi 18 F-FDG under 2% isoflurane anesthesia. The same rats were treated with atomoxetine 1 mg/kg, 30 mins before 18 F-FDG administration. Rats were awake for 60 mins and subsequently anesthetized for upper-body Inveon MicroPET/CT scan. To evaluate whether enhanced 18 F-FDG uptake in activated BAT could be reduced by pharmacologic interventions, propranolol (b3adrenorecptor inhibitor) 5 mg/kg was given intraperitoneally in anesthetized rats, 30 minutes prior to tomoxetine administration. For NET imaging, 11 C-TAZA (4-11 C-methylamino-4 0 -dimethylaminoazobenzene) and 11 C-Dalene (4-methylamino-4 0 -(N-11 Cmethyl-N-methylamino)stilbene) were administered iv (B0.5-3 mCi) and scanned in Inveon PET/CT for 90 mins. Competition studies were done with atomoxetine (preinjection, 1-2 mg/kg). PET/CT data was analysed using IRW and PMOD.
Results: Tomoxetine increased the average 18 F-FDG uptake of IBAT significantly, > 15 times, compared to controls (365 ± 170 vs. 23.9 ± 8.7 kBq/cc) (Figure 1 ). This is consistent with blocking of NET by atomoxetine and increasing norepinephrine. Propranolol (adrenergic receptor inhibitor) reduced the average 18 F-FDG uptake of IBAT significantly. Interscapular BAT (IBAT) was clearly visualized with both 11 C-TAZA and 11 C-Dalene with IBAT to reference muscle ratios > 4. Atomoxetine reduced IBAT binding of both 11 C-TAZA and 11 C-Dalene by 60% and 35%, respectively. Incomplete displacement may be due to possible internalization of the radiotracers.
Although there was similarity in the different BAT regions visualized by atomoxetine stimulated 18 F-FDG uptake and NET agents 11 C-TAZA and 11 C-Dalene, 18 F-FDG uptake appeared more prominent. Autoradiography of IBAT and white adipose tissue (WAT) confirmed the data obtained by PET.
Conclusions: Our studies suggest that 11 C-TAZA and 11 C-Dalene are effective imaging agents for NET in BAT. Atomoxetine increases norepinephrine in BAT resulting in hypermetabolic effects measurable by 18 F-FDG uptake at ambient temperature in the rodent model. Correlations of NET binding of 11 C-TAZA and 11 C-Dalene and 18 F-FDG uptake in various BAT regions is underway in order to assess the relationship of NET concentration with metabolic activity. Acknowledgements: NIH/NIDDK R21DK092917, RC1DK087352. Human PET data was analyzed by kinetic modeling using metabolite-corrected arterial input functions and by an AUC method similar to that used in monkey.
Results: The kinetics and distribution of [ 18 F]MK-0911 in monkey and human brain were similar, with rapid distribution into all grey matter regions including cortex, striatum, and thalamus followed by moderate clearance. Lowest distribution was observed in the cerebellum and white matter, consistent with the known distribution of ORL1 [3] . [1] . [ 11 C]PIB is currently the foremost useful PET radioligand for imaging b-amyloid plaques [2] . There remains a need for radioligands with a greater dynamic imaging range coupled with a longer-lived fluorine-18 label. To meet this need, we sought to design radioligands with higher binding affinity and lower lipophilicity than [ 11 C]PIB, and with amenability to labeling with fluorine-18. Here we report the synthesis, radiolabeling and PET imaging in monkey of three candidate 18 F-labeled ligands for imaging b-amyloid plaque. Methods: Ligands (FNIMHa-c) and labeling precursors were synthesized (Scheme). The key synthesis step was fluorination of the chloro-precursor under Bu 4 NCl catalysis. Each radioligand was prepared in a modified GE FX Box by treating the appropriate chloro precursor with [ 18 F]fluoride ion in DMF, followed by deprotection with neat TFA. Ligands were assayed for binding to b-amyloid in AD brain tissue homogenate with [ 3 H]PIB as reference radioligand. Autoradiography on both healthy and AD brain tissue slices (14 mm) was performed with each radioligand, in the presence and absence of PIB (1.0 mM). Each 18 F-labeled ligand was injected intravenously into normal rhesus monkey and the brain was dynamically scanned for 120 min with an animal PET scanner (Focus 220, resolution: 1.6 mm). Decay-corrected regional brain time-activity (SUV) curves were obtained.
Results: Decay-corrected radiochemical yields of the purified and isolated 18 F-labeled ligands were 3050%. The retention times of FNIMHa and PIB in HPLC showed that they have very close lipophilicities. Formulated radioligands were stable for more than 4 h at room temperature. Binding affinities (K i ) for FNIMHa-c were 20, 12, and 5 nM, respectively. Autoradiography with [ 18 F]FNIMHa showed specific binding to b-amyloid plaques from AD brain slices, which could be blocked with PIB ( Figure: left panel). For each radioligand, PET imaging in normal rhesus monkey showed high initial uptake and rapid washout of radioactivity within 2 h of imaging. [ 18 F]FNIMHa showed low and quite uniform brain radioactivity concentration at less than 1 h after injection; radioactivity in white matter was similar to that in other regions (Figure; right panel Methods: Ten healthy participants without history of neurological or psychiatric illness (seven male, median age 46 (25-62) years) each had a 90-minute PET scan using a Siemens/CTI ECAT EXACT3D 962 HR + PET camera following a median injection of 186 (173-192) MBq [ 18 F]GE-179. Continuous arterial blood sampling over the first 15 minutes was complemented by discrete blood sampling over the duration of the scan. Metabolite-corrected parent plasma input functions were generated using CLICKFIT (v1.7) software. Dynamic images were motion-corrected. Weighted summation images (KBq/ml) were created with Receptor Parametric Mapping (RPM6), and co-registered with corresponding 3T T1-weighted MR images. Global uptake was calculated, as was uptake in six bilateral grey matter regions-of-interest (ROIs) obtained via anatomical segmentation of the MRI (MAPER; Heckemann et al., 2011). Volume-of-distribution (VT) was quantified in those ROIs with one-, two-and three compartment(s) models in CLICKFIT. Parametric VT images were generated by graphical analysis (Logan, 2003) using RPM6 (Figure 1) . Results: [ 18 F]GE-179 accounted for a mean of 37% of plasma radioactivity at 30 minutes post-injection. The mean grey-matter radioactivity concentration peaked at 9 KBq/ml at t = 7.5 minutes, and remained higher than that of white matter over 90 minutes. The highest median ratio of grey:white matter radioactivity concentration (1.8) was seen in early (t = 5-30 minutes) summation images. The radioactivity concentration was highest in putamina, occipital lobes, and thalami, and lowest in the temporal lobes. The twocompartment, four rate constants model best de-scribed the radioligand's kinetics in grey matter, as assessed by the Akaike Information Criterion (AIC), with acceptable ( < 17%) regional between-subject coefficients of variation. There was no correlation between VT and k1 in any ROI. Conclusions: [ 18 F]GE-179 exhibits high brain penetration with a heterogeneous distribution, moderately-paced kinetics in grey matter, acceptable between-subject variability, and rapid metabolism. Reliable quantification appears feasible using a twocompartment model. The lower uptake in the temporal lobes might relate to higher expression of NR2B than NR2A subunits with lower channel open probability. Further evaluation of [ 18 F]GE-179 should facilitate investigation of activated NMDA receptor availability in a variety of conditions. P096. Consortium to develop an alpha-synuclein imaging agent Jamie Eberling 1 , Andrew Medhurst 2 , Kevin Nash 2 , Andrew Gill 2 , Scott Pollack 2 , David Cronk 2 , Brian Bacskai 3 , Chester Mathis 4 and Robert Mach 5
Background: The Michael J. Fox Foundation (MJFF) is supporting a consortium with the goal of developing a PET radiotracer to image the distribution of alphasynuclein in the brain. The accumulation of aggregated alpha-synuclein in the brain is the pathological hallmark of Parkinson's disease and is a frequent target for drugs being developed to treat PD. The ability to visualize alpha-synuclein in the brain could be useful both as a biomarker of the presence of disease and disease progression and as a tool for drug development. Methods: Four groups have been selected by MJFF to participate in the consortium including three aca-demic groups and a contract research organization (BioFocus). These groups are working to identify and test compounds that can ultimately be radiolabeled and used as PET imaging agents. Results: Two approaches were pursued to identify compounds that bind to aggregated alpha-synuclein. The first approach utilized a competition binding assay using either the fluorescent ligand Thioflavin T or the radioligand [3H]-Chrysamine G. Following assay optimization, approximately 100,000 compounds selected from the BioFocus libraries were screened in both assay formats at a single concentration of 10 micro- molar. From the Thioflavin T screen, approximately 2,000 compounds showing > 45% inhibition of binding were selected for hit confirmation at 10 micromolar in duplicate, and 263 of these compounds proceeded to IC50 potency determination. Selectivity of these compounds was determined against aggregated betaamyloid and tau using Thioflavin T and Thioflavin S assays respectively. The second approach utilized a Surface Plasmon Resonance (SPR) based Biacore assay developed to investigate the direct binding of com-pounds to monomeric alpha-synuclein, aggregated alpha-synuclein and aggregated beta-amyloid, immobilized to Biacore CM5 chips via amine coupling reactions. Following the screening of approximately 3,500 compounds against these three protein targets, 120 compounds were selected for KD determination. Conclusions: Further characterization of interesting compounds identified from these approaches is ongoing, including binding studies in PD brains with Lewy body pathology.
P097. In vivo PET imaging of cerebral 5-HT 7 receptors with novel radioligands 5-HT 7 receptor due to a good brain uptake and since it can be selectively blocked by SB-269970.
Background: Positron emission tomography (PET) can be used to assess alterations in neurotransmitter levels in vivo in a non-invasive manner, as convincingly demonstrated for the dopamine system. The prospects for imaging endogenous serotonin (5-HT) release are improved by the introduction of 5-HT 1B receptor partial agonist radioligands, e.g., [ 11 C]AZ10419369, where binding is reduced in a dose-dependent manner by intravenous fenfluramine adminstration. The aim of this study was first to optimize a bolus/infusion scheme for [ 11 C]AZ10419369 in the rhesus monkey to allow for a within-scan challenge and secondly, to calculate the AZ10419369 in vivo dissociation constant (K d ). Methods: Anesthetized rhesus macaques underwent PET-and MR-scanning with a 3T Tim Trio with a BrainPET insert inside the bore of the scanner; data were acquired continuously for up to 150 min. The 5-HT 1B receptor radioligand [ 11 C]AZ10419369 was given as different bolus plus infusion schedules with Kbol ranging from 1.3 h to 3 h. Regional timeactivity curves were retrieved by delineating brain regions on the anatomical MRI-image. Sixtyfive min after bolus injection, either 10 mg of AZ10419369 was given as an i.v. bolus injection or the 5-HT releaser fenfluramine (5 mg/kg) was infused i.v. over 5 min. Cerebral 5-HT 1B receptor binding BP ND was quantified at steady-state with cerebellum as the reference region. The occupancy was calculated based on fitting of the displacement curve assuming a k off = 0.02 min À1 (1) and the free fraction in cerebellum (f ND ) was determined based on plasma water concentration of [ 11 C]AZ10419369. In vivo K d of the radiotracer was calculated as: Kd = -((F*O)-F)/O), where O is the occupancy and F is the free fraction of AZ10419369 after the challenge injection. Results: Time-activity curves of [ 11 C]AZ10419369 showed that a Kbol of 1.8 h generated steady-state levels in both high and low binding regions as early as 35 min after injection whereas Kbol values of 2.6-3 h, resulted in steady state levels at 55-75 min, leading to difficulties in accurate quantification of within-scan challenge studies. The free fraction of [ 11 C]AZ10419369 in cerebellum, f ND , was determined to 0.008. I.v. injection of 10 mg AZ10419369 lead to a conservative estimate of 33 % occupancy of the 5-HT 1B receptors and accordingly, a K d was determined to 0.017 nM. Fenfluramine infusion led to a B30% reduction in occipital cortex BP ND measured 30 min post infusion of fenfluramin. An immediate and transient increase in [ 11 C]AZ10419369 was also observed after injection of fenfluramine similar to what has previously been reported (2) . Conclusions: A bolus/infusion scheme of 1.8 h is optimal for obtaining steady state in high and low binding regions as fast as possible. An in vivo K d of 0.017 nM means that a maximum of 1.19 mg of AZ10419369 can be injected in order to keep occupancy below 5%.
